Deep Dive
Industry insights from our journalists
-
No one knows the size of the NASH market
Industry is still using a broad estimate for the NASH population, which has led to very different views on the size of the potential market opportunity.
Jacob Bell • May 16, 2019 -
On the path to patients, NASH drugs may hit a payer roadblock
Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.
Jacob Bell • May 15, 2019 -
Will a big needle burst the NASH bubble?
With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market.
Jacob Bell • May 14, 2019 -
Pharma, late to digital game, rushes to catch up
In the past two years, six of the largest pharmas appointed chief digital or information officers to top management for the first time, a signal of growing industry interest in revamping how it does business.
Ned Pagliarulo • May 13, 2019 -
Biopharma happily takes the tax cuts, but the jobs are harder to find
The tax burden of U.S.-based drugmakers shrank by nearly one-quarter following the 2017 Republican tax bill, but jobs edged up only slightly, a BioPharma Dive analysis found.
Jonathan Gardner • May 09, 2019 -
Aducanumab's failure puts pressure on field to look beyond amyloid
"At this point, we've done the right experiment and the hypothesis didn't hold true," said Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.
Ned Pagliarulo • March 22, 2019 -
Unblinded: Scott Gottlieb on biosimilars' precarious moment and the gene therapy boom
The outgoing FDA chief spoke with BioPharma Dive a day before his surprise resignation, detailing how drugmaker "shenanigans" have evolved and weighing in on gene therapy's inflection point.
Andrew Dunn • March 12, 2019 -
Pharma is shuffling around jobs, but a skills gap threatens the process
Drugmakers have found difficulty luring employees who can work with the latest technologies away from the likes of Amazon and Google, for instance.
Jacob Bell • Feb. 04, 2019 -
A flashy 2019 start to pharma M&A, but will it last?
Recent high-profile acquisitions don't fully clear up what the buyer's market will look like in an expected bumper year for dealmaking.
Jacob Bell • Jan. 22, 2019 -
How a 'regulatory dead zone' may be holding up copycat insulin
The FDA has talked up biosimilars' potential impact on the insulin market, but changing regulations have complicated matters for would-be competitors.
Andrew Dunn • Jan. 14, 2019 -
At JPM, the NASH flood gates start to crack
Multiple late-stage results are slated for 2019, bringing to the forefront a question of how battle lines will be drawn across the market.
Jacob Bell • Jan. 11, 2019 -
Hunting productivity, drugmakers pitch new 'pillars' of R&D
By some measures, returns on R&D have fallen to decade lows. Pharmas and biotechs, however, argue new technologies could open faster paths to market.
Ned Pagliarulo • Jan. 11, 2019 -
3 questions leaving ASH
Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers.
Jacob Bell • Dec. 05, 2018 -
At ASH, bispecific cancer therapies make a mark
The therapies work to guide tumor-fighting immune cells to target cancerous invaders. Research at ASH suggests they could be another avenue of attack in immuno-oncology.
Ned Pagliarulo and Jacob Bell • Dec. 05, 2018 -
Executive of the Year: Emma Walmsley, GlaxoSmithKline
Since taking the helm, Walmsley has launched an R&D restructure, shaken up GSK's top leadership and reset a corporate strategy that's failed to deliver industry-leading growth.
Ned Pagliarulo • Dec. 03, 2018 -
Memorial Sloan Kettering scandal raises questions for pharma's biggest corporate boards
A review of corporate board membership found about two-thirds of the largest drugmakers had at least one director who also had a leadership role in a nonprofit healthcare organization.
Andrew Dunn • Nov. 29, 2018 -
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
The therapy lags its competitors in getting to market, but clinical data could make filgotinib stand out. How much would a late arrival hurt its prospects?
Andrew Dunn • Nov. 26, 2018 -
Red pill or blue? It could be a billion-dollar decision
Viagra and Nexium underscore how marketers and manufacturers can use color to make a drug franchise more successful.
Jacob Bell • Oct. 29, 2018 -
First Amendment takes center stage in DTC price fight
A string of court decisions have bolstered commercial speech rights for industry. The Trump administration's push to require prices in TV ads could become the next legal battleground.
Andrew Dunn • Oct. 22, 2018 -
Pharma's slow embrace of continuous manufacturing
On the whole, drugmakers remain wedded to traditional production methods that have served for decades. Some, however, are shifting to newer technology.
Ned Pagliarulo • Sept. 24, 2018 -
For CDMOs, continuous manufacturing isn't an 'if,' but a 'how'
Contract services providers are receiving more interest from drugmakers keen on the technology's potential cost-savings and better efficiency.
Jacob Bell • Sept. 24, 2018 -
As FDA and pharma warm to continuous manufacturing, generics stay skeptical
Generics companies worry continuous manufacturing could become another tool for branded drugmakers to protect their products.
Andrew Dunn • Sept. 24, 2018 -
FDA confronts its limits in push on drug pricing
Legally, regulating prices is outside of the FDA's purview. But that hasn't stopped Scott Gottlieb from taking a more vocal approach to the hot-button issue than past FDA chiefs.
Ned Pagliarulo • Aug. 27, 2018 -
FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?
Regulators are using incentives to spur development of much-needed drugs. The results so far have been mixed.
Jacob Bell • Aug. 27, 2018 -
How Scott Gottlieb is upending FDA communication, one tweet at a time
The FDA commissioner has relentlessly pumped out tweets, statements and more. But how has that affected FDA communications and the agency overall?
Andrew Dunn • Aug. 27, 2018
